Elsevier

Lung Cancer

Volume 83, Issue 2, February 2014, Pages 211-218
Lung Cancer

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

https://doi.org/10.1016/j.lungcan.2013.11.006Get rights and content

Abstract

Objectives

Four randomized phase II/III trials investigated the addition of cetuximab to platinum-based, first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). A meta-analysis was performed to examine the benefit/risk ratio for the addition of cetuximab to chemotherapy.

Materials and methods

The meta-analysis included individual patient efficacy data from 2018 patients and individual patient safety data from 1970 patients comprising respectively the combined intention-to-treat and safety populations of the four trials. The effect of adding cetuximab to chemotherapy was measured by hazard ratios (HRs) obtained using a Cox proportional hazards model and odds ratios calculated by logistic regression. Survival rates at 1 year were calculated. All applied models were stratified by trial. Tests on heterogeneity of treatment effects across the trials and sensitivity analyses were performed for all endpoints.

Results

The meta-analysis demonstrated that the addition of cetuximab to chemotherapy significantly improved overall survival (HR 0.88, p = 0.009, median 10.3 vs 9.4 months), progression-free survival (HR 0.90, p = 0.045, median 4.7 vs 4.5 months) and response (odds ratio 1.46, p < 0.001, overall response rate 32.2% vs 24.4%) compared with chemotherapy alone. The safety profile of chemotherapy plus cetuximab in the meta-analysis population was confirmed as manageable. Neither trials nor patient subgroups defined by key baseline characteristics showed significant heterogeneity for any endpoint.

Conclusion

The addition of cetuximab to platinum-based, first-line chemotherapy for advanced NSCLC significantly improved outcome for all efficacy endpoints with an acceptable safety profile, indicating a favorable benefit/risk ratio.

Introduction

The treatment of advanced non-small cell lung cancer (NSCLC), which encompasses a number of different histological subtypes [1], remains one of the great challenges of contemporary medical oncology. Approximately 40% of patients with NSCLC present with unresectable metastatic stage IV tumors [2], [3]. Systemic chemotherapy (with or without bevacizumab) or tyrosine kinase inhibitor (TKI) therapy (in particular for patients whose tumors have activating mutations of the epidermal growth factor receptor gene [EGFR]) represent the primary treatment options to extend survival and improve quality of life for this patient group [4], [5], [6], [7], [8], [9], [10], [11]. In the majority of patients of good performance status, first-line chemotherapy regimens generally are based on cytotoxic doublets comprising a platinum analog combined with either vinorelbine, gemcitabine, docetaxel, paclitaxel, or pemetrexed (only for patients with non-squamous disease). A series of randomized trials has suggested that the different standard doublets provide similar levels of efficacy in the first-line treatment of NSCLC [12], [13], [14], [15], [16].

The addition to first-line doublets of a third, concurrently administered, cytotoxic agent has been shown to increase toxicity without improving overall survival [5], [13], [17]. However, the phase III First-Line ErbituX in lung cancer (FLEX) trial in patients with EGFR-expressing NSCLC showed that combining the EGFR antibody cetuximab with cisplatin and vinorelbine significantly improved overall survival in this setting (hazard ratio, HR, 0.871, 95% CI 0.762–0.996; p = 0.044) [18]. Enrollment of the 1125 patients included in the intention-to-treat (ITT) population of this large multinational trial was independent of NSCLC histology but required some degree of tumor EGFR protein expression. A second phase III trial exploring chemotherapy plus cetuximab in this setting, BMS099, which included an ITT population of 676 patients with advanced NSCLC, reported a survival benefit of similar magnitude for the addition of cetuximab to taxane (paclitaxel or docetaxel) plus carboplatin chemotherapy compared with chemotherapy alone (HR 0.89, 95% CI 0.75–1.05; median 9.7 vs 8.4 months), although in this case, the difference between the treatment arms was not statistically significant (p = 0.169) [19]. Tumor EGFR expression was not an eligibility requirement in the BMS099 trial.

We performed a meta-analysis of individual patient data from randomized trials in which chemotherapy plus cetuximab was compared with chemotherapy alone in the first-line treatment of advanced NSCLC. Meta-analyses of individual patient data can offer certain advantages over those based on aggregate or summary data [20]; in particular, the use of individual patient data allows for a more complete analysis, including the study of interaction between the treatment effect and covariates [21]. Our intention was to provide an overall appraisal of the benefit/risk ratio associated with the addition of cetuximab to platinum-based chemotherapy as first-line treatment for advanced NSCLC and to explore treatment outcome in subgroups defined by baseline characteristics of particular interest.

Section snippets

Selected trials

Four randomized trials which compared platinum-based chemotherapy with or without cetuximab as first-line treatment for patients with advanced NSCLC have been reported [18], [19], [22], [23]. Individual patient efficacy and safety data from these four trials were included in the current meta-analysis. Subsequent electronic searches of publication databases did not identify any relevant additional trials that were eligible for inclusion.

Individual patient data

Individual patient data were collected for all patients in

Selected trials and inclusion criteria

Four open-label randomized trials, contributing a total of 2018 ITT patients corresponding to 100% of the randomized patients, were included in the meta-analysis, with 1003 patients randomly assigned to receive chemotherapy plus cetuximab and 1015 to receive chemotherapy alone [18], [19], [22], [23]. Treatment regimens and trial characteristics are summarized in Table 1. The combined safety population, which corresponded to 100% of the patients starting protocol treatment in each of the four

Discussion

The current meta-analysis, which was based on 2018 patients, 56% of whom were enrolled in the phase III FLEX trial, confirmed for all efficacy endpoints a modest benefit associated with the addition of cetuximab to standard platinum-based doublets in the first-line treatment of advanced NSCLC. Three published meta-analyses [26], [27], [28] based on aggregate data from the same four randomized trials reached similar conclusions to the current study regarding the benefit of adding cetuximab to

Conclusion

As suggested by the absence of significant heterogeneity between trials, this meta-analysis has demonstrated a consistent benefit in all efficacy endpoints for the addition of cetuximab to standard, platinum-based chemotherapy doublets used in the first-line treatment of advanced NSCLC. The meta-analysis also demonstrates that the safety profile of chemotherapy plus cetuximab in this setting compared with chemotherapy alone is acceptable.

Conflict of interest statement

Regarding the work under consideration: J-LP declared receiving a consultancy fee/honorarium and support for travel to meetings from Merck Serono; RP, KJO’B and NT declared receiving consultancy fees/honoraria, support for travel to meetings and fees for participating in reviews of study results from Merck Serono; TJL declared receiving support for travel to meetings from Bristol-Myers Squib (BMS); CAB declared receiving per case funding for the original trial from study sponsor BMS and

Funding sources and any writing assistance

The sponsor of this study, Merck KGaA, Darmstadt, Germany, was responsible for statistical analysis. Data were interpreted by the sponsor in collaboration with the authors. The sponsor commissioned the drafting of our report. Jim Heighway of Cancer Communications & Consultancy Ltd. (Knutsford, UK) provided medical writing services, which were funded by the sponsor. J-LP had the final responsibility for the decision to submit the manuscript for publication.

References (39)

  • R. Makitaro et al.

    Prospective population-based study on the survival of patients with lung cancer

    Eur Respir J

    (2002)
  • A.L. Potosky et al.

    Population variations in the initial treatment of non-small-cell lung cancer

    J Clin Oncol

    (2004)
  • C.Q. Zhu et al.

    Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

    J Clin Oncol

    (2008)
  • P.A. Bunn et al.

    Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion

    Oncologist

    (2008)
  • S. Ramalingam et al.

    Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions

    Oncologist

    (2008)
  • T.S. Mok et al.

    Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

    N Engl J Med

    (2009)
  • A. Sandler et al.

    Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

    N Engl J Med

    (2006)
  • C.G. Azzoli et al.

    American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

    J Clin Oncol

    (2009)
  • P.A. Bunn

    Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

    J Clin Oncol

    (2002)
  • Cited by (68)

    • Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer

      2022, Cancer/Radiotherapie
      Citation Excerpt :

      Cetuximab blocks EGF's binding to EGFR's extracellular domain. Combining cetuximab with chemotherapy regimens in patients with metastatic non-small-cell lung cancer has revealed cetuximab to be effective, with manageable toxicity [7]. Preclinically, cetuximab amplified the chemotherapy response and displayed radiosensitizing properties [8].

    • Antitumor activity of a lectibody targeting cancer-associated high-mannose glycans

      2022, Molecular Therapy
      Citation Excerpt :

      The remarkable in vivo antitumor efficacy observed with AvFc is most likely due to its effective binding to high-mannose glycans that are broadly and highly accumulated on the surface of cancer cells; in our ongoing study, AvFc showed a similar antitumor effect protecting against B16F10 melanoma lung metastasis, while the non-sugar-binding mutant AvFclec− failed to show any effect (unpublished data). Despite the fact that colorectal cancer patients show significant improvements in response rates, overall survival, and progression-free survival after CTX treatment, CTX responses in NSCLC patients have not been convincing in clinical trials.42–44 IGF1R may be involved in the resistance mechanism of CTX and other EGFR-targeted drugs,45–48 as these two receptors share similar downstream signaling pathways (phosphatidylinositol 3-kinase [PI3K]/AKT/MAPK/nuclear factor κB [NF-κB]); IGF1R can bypass EGFR inhibition, while their cooperation may promote tumor growth and progression.47–49

    • Gender and outcomes in non-small cell lung cancer: An old prognostic variable comes back for targeted therapy and immunotherapy?

      2018, ESMO Open
      Citation Excerpt :

      In our analysis, because all patients had sensitising mutations in EGFR, the treatment was given in first line and the comparison arm was chemotherapy, the results are less likely of being influenced by a cofounding variable, although our analysis does not consider ethnicity or smoking status. Despite the additional benefit from EGFR TKI seen in women, a meta-analysis by Pujol et al37 did not show a difference in benefit from cetuximab, an anti-EGFR antibody between genders in the subgroup analysis.37 In the review of other biological agent, bevacizumab, the effect of gender has contradicting results.

    View all citing articles on Scopus
    View full text